Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2025-12-25 @ 9:55 PM
Study NCT ID:
NCT03402958
Status:
COMPLETED
Last Update Posted:
2018-09-21
First Post:
2018-01-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
General Practitioner's Place in the Treatment of Fracture Osteoporosis in the Elderly
Sponsor:
Rennes University Hospital
Organization:
Study Overview
Official Title:
General Practitioner's Place in the Treatment of Fracture Osteoporosis in the Elderly
Status:
COMPLETED
Status Verified Date:
2018-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GEOFRAGE
Brief Summary:
Osteoporosis is a major public health problem. Its screening and its treatment remain largely insufficient while therapies have demonstrated their effectiveness. In the event of a severe fracture, the update of the 2016/2017 recommendations, prepared by the Research and Information Group on Osteoporosis and the French Rheumatology Society, concerning osteoporosis recommends a specific treatment with bisphosphonates as first-line treatment, without bone densitometry, regardless of age. The frequency of prescribing anti-osteoporotic treatment as an outpatient after a fracture of the upper extremity of the femur is very low (2% to 21% according to the studies). The main factors associated with non-prescription found are co-morbidities (charlson score\> 6), dementia, obesity (BMI\> 30), chronic alcoholism, male sex, polypharmacy\> 4, age. Conversely, the factors associated with prescribing are recurrent falls (\> 2 / year), a history of osteoporotic fracture, an Iso Resource Group\> 3, female sex, and corticosteroid therapy.
Detailed Description:
1. / The collection of patients' characteristics upon admission will be based on the computerized patient file and the paper file: socio-demographic data, co-morbidities, functional status, entry / exit treatments, place of residence, source, balance sheet hospital.
2. / Determination with the treating doctor or the pharmacist of the prescriptions of the anti-osteoporotic treatments at 6 months of the hospital care.
3. / Research factors associated with the prescription (or non-prescription) of anti-osteoporotic treatments.
2. / Determination with the treating doctor or the pharmacist of the prescriptions of the anti-osteoporotic treatments at 6 months of the hospital care.
3. / Research factors associated with the prescription (or non-prescription) of anti-osteoporotic treatments.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: